Sign In
Buy NVAX
$10.20
-0.0100 (-0.0979%)
At Close: Jun 03, 2026
2 Beaten-Down Stocks Near Their 52-Week Lows That Aren't Worth Buying
07:15am, Saturday, 15'th Mar 2025
Buying stocks after they have lost significant market value can lead to excellent returns in the long run, but only if the company in question can reverse its fortunes.
Novavax, Inc. (NVAX) Leerink Partners 2025 Global Healthcare Conference (Transcript)
07:48pm, Tuesday, 11'th Mar 2025
Novavax, Inc. (NASDAQ:NVAX ) Leerink Partners 2025 Global Healthcare Conference March 11, 2025 12:00 AM ET Company Participants John Jacobs - CEO Ruxandra Draghia - Head of R&D Jim Kelly - CFO Confere
Novavax Announces Changes to Board of Directors
08:00am, Tuesday, 11'th Mar 2025
James Young, PhD retires as Chair of the Board, Margaret McGlynn, RPh, appointed John Shiver, PhD appointed to board of directors GAITHERSBURG, Md. , March 11, 2025 /PRNewswire/ -- Novavax, Inc. (Nasd
Novavax, Inc. (NVAX) TD Cowen 45th Annual Health Care Conference (Transcript)
01:34pm, Tuesday, 04'th Mar 2025
Novavax, Inc. (NASDAQ:NVAX ) TD Cowen 45th Annual Health Care Conference March 4, 2025 9:10 AM ET Company Participants John Jacobs - President and Chief Executive Officer Ruxandra Draghia - Executive
Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock
10:05am, Tuesday, 04'th Mar 2025
Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Novavax Q4 Earnings Review: Long-Term Downsizing Plan Suggests Sell Rating
11:16am, Friday, 28'th Feb 2025
Novavax, Inc.'s Q4 2024 earnings — released yesterday — show a significant revenue decline and continued losses, despite cost-cutting measures and the deal with Sanofi, worth up to $1.2bn. The com
1 Biotech Stock to Buy in 2025, and 1 to Avoid
08:00am, Friday, 28'th Feb 2025
Viking Therapeutics (VKTX 3.06%) and Novavax (NVAX -3.55%) were two of the big winners in the biotech industry last year. Both companies saw their shares rise significantly; the former had exciting cl
Novavax to Participate in Upcoming March Investor Conferences
04:05pm, Thursday, 27'th Feb 2025
GAITHERSBURG, Md. , Feb. 27, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), today announced that the management team will participate in the following upcoming investor conferences: TD Cowen 45 th
Novavax Q4 Loss Narrower Than Expected, Sales Beat Estimates
01:20pm, Thursday, 27'th Feb 2025
NVAX reports encouraging fourth-quarter results. It completes the sale of its Czech Republic manufacturing unit to Novo Nordisk for $200 million.
Novavax, Inc. (NVAX) Q4 2024 Earnings Call Transcript
11:42am, Thursday, 27'th Feb 2025
Novavax, Inc. (NASDAQ:NVAX ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Luis Sanay - Vice President, Investor Relations John Jacobs - President and Chief Execut
Novavax Reports Smaller Q4 Loss, Shifts Focus From Commercializing COVID-19 Vaccine To Maximize Value
11:24am, Thursday, 27'th Feb 2025
On Thursday, Novavax Inc NVAX reported fourth-quarter 2024 sales of $88.31 million, compared to $291 million a year, beating the consensus of $84.35 million. The decrease was due to lower product
Novavax (NVAX) Reports Q4 Loss, Tops Revenue Estimates
10:15am, Thursday, 27'th Feb 2025
Novavax (NVAX) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $1.44 per share a year ago.
Novavax's quarterly loss shrinks as it ramps down spending on COVID vaccines
08:06am, Thursday, 27'th Feb 2025
Novavax's fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 vaccines, its only product on the market.
Novavax Stock Is Rising. Revenue Beat Estimates.
08:05am, Thursday, 27'th Feb 2025
Fourth-quarter revenue came in at $88 million, above expectations of 84 million, while Novavax continues to shift away from Covid-19 vaccines.
Novavax Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
08:00am, Thursday, 27'th Feb 2025
Transitioned lead commercial responsibility of Nuvaxovid™ COVID-19 vaccine to Sanofi beginning with the 2025-2026 season Achieved total revenue of $88 million in the fourth quarter of 2024 and $682
